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Key points
 Myostatin is an important regulator of muscle mass and a potential therapeutic target for the
treatment of diseases and injuries that result in muscle atrophy.
 Targeted genetic mutations of myostatin have been generated in mice, and spontaneous
loss-of-function mutations have been reported in several species. The impact of myostatin
deficiency on the structure and function of muscles has been well described for mice, but not
for other species.
 We report the creation of a genetic model of myostatin deficiency in rats using zinc finger
nuclease technology.
 The main findings of the study are that genetic inactivation of myostatin in rats results in
increases in muscle mass without a deleterious impact on the specific force production and
tendon mechanical properties. The increases in mass occur through a combination of fibre
hypertrophy, hyperplasia and activation of the insulin-like growth factor-1 pathway, with no
substantial changes in atrophy-related pathways.
 This large rodent model has enabled us to identify that the chronic loss of myostatin is void of
the negative consequences tomuscle fibres and extracellularmatrix observed inmousemodels.
Furthermore, the greatest impact of myostatin in the regulation of muscle mass may not be to
induce atrophy directly, but rather to block hypertrophy signalling.
Abstract Myostatin is a negative regulator of skeletal muscle and tendon mass. Myostatin
deficiency has been well studied inmice, but limited data are available on howmyostatin regulates
the structure and function of muscles and tendons of larger animals. We hypothesized that, in
comparison to wild-type (MSTN+/+) rats, rats in which zinc finger nucleases were used to
genetically inactivate myostatin (MSTN/) would exhibit an increase in muscle mass and total
force production, a reduction in specific force, an accumulation of type II fibres and a decrease and
stiffening of connective tissue. Overall, the muscle and tendon phenotype of myostatin-deficient
rats was markedly different from that of myostatin-deficient mice, which have impaired contra-
ctility and pathological changes to fibres and their extracellularmatrix. Extensor digitorum longus
and soleus muscles ofMSTN/ rats demonstrated 20–33% increases in mass, 35–45% increases
in fibre number, 20–57% increases in isometric force and no differences in specific force. The
insulin-like growth factor-1 pathway was activated to a greater extent in MSTN/ muscles, but
no substantial differences in atrophy-related genes were observed. Tendons ofMSTN/ rats had
a 20% reduction in peak strain, with no differences in mass, peak stress or stiffness. The general
morphology and gene expression patterns were similar between tendons of both genotypes. This
large rodent model of myostatin deficiency did not have the negative consequences to muscle
fibres and extracellular matrix observed in mouse models, and suggests that the greatest impact
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of myostatin in the regulation of muscle mass may not be to induce atrophy directly, but rather
to block hypertrophy signalling.
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Introduction
Myostatin (GDF-8) is a member of the transforming
growth factor-β superfamily of cytokines and a negative
regulator of muscle mass. Myostatin binds to the activin
type IIB (ACVR2B) and type IB (ACVRB) receptors and
activates the Smad2/3, p38MAPKandErk1/2 signal trans-
duction pathways (Gumucio &Mendias, 2012). Mice that
are deficient in myostatin have an up to twofold increase
in muscle mass, and administration of recombinant myo-
statin leads to profound atrophy and cachexia (McPherron
et al. 2006; Zimmers et al. 2002). Myostatin also regulates
the fibre-type composition of skeletal muscles, with
myostatin-deficientmice demonstrating an increase in the
accumulation and size of type II muscle fibres compared
with control animals (Gentry et al. 2011). The lack ofmyo-
statin results in no change or an increase in production
of maximal isometric force (Po), and for some muscles
there is also a decrease in specific force (sPo), which is Po
normalized tomuscle cross-sectional area (CSA) (Mendias
et al. 2006, 2011; Gentry et al. 2011; Qaisar et al. 2012).
As well as controlling muscle fibre size, type and contra-
ctility, myostatin also regulates the composition of the
muscle and tendon extracellular matrix (ECM), in part by
directly inducing the expression of type I collagen (Li et al.
2008;Mendias et al. 2008).While the targeted inhibition of
myostatin has the potential to prevent muscle atrophy and
fibrosis in degenerative diseases and injuries, the negative
effects on force production and ECM stiffening observed
in mouse models of myostatin deficiency have provided
some pause in the potential therapeutic use of myostatin
inhibitors.
In addition to mice, several animal models of myo-
statin deficiency have been described in the literature,
including cattle, sheep, dogs, pigs and trout, as well
as humans (Stinckens et al. 2011). While all organisms
with deficiencies of myostatin display gross skeletal
muscle hypertrophy, other than a common observation
of increased muscle mass and limited data on fibre-type
changes, there have beennodetailed analyses of the impact
of myostatin deficiency on the structure, mechanics and
biochemistry of muscles from organisms other than mice.
Recent advances in the ability to manipulate the rat
genome using zinc finger technology have allowed for the
inactivation of specific genes in the genome of rats (Geurts
et al. 2009). Rats are 10–20 times larger thanmice, and the
skeletal muscle architecture, fibre-type composition and
contractile functionmore closely resembleshumanmuscle
than mouse muscle (Eng et al. 2008). As the rat offers
several advantages overmousemodels, both for improving
our understanding of basic muscle physiology and in
the design of new therapies for muscle diseases, our
objective was to evaluate the impact of myostatin
deficiency on the contractile function,muscle architecture
and fibre-type composition of skeletal muscles from rats
with a targeted inactivation of their myostatin gene.
We hypothesized that, compared with wild-type control
(MSTN+/+) rats, rats with a targeted knock-out of myo-
statin (MSTN/) would exhibit an increase in muscle
mass and total force production, a reduction in specific
force production, an increased accumulation of type II
muscle fibres, a decrease in connective tissue content and
a stiffening of tendons.
Methods
Animals
This study was approved by the University of Michigan
institutional animal care and use committee (protocol
number PRO00003566). Animal handling and care was
performed in accordance with US Public Health Service
Policy on Humane Care and Use of Laboratory Animals
and in agreement with the UK Home Office standards on
research and testing using animals.
Myostatin-deficient rats (MSTN/; strain SS-Mstnem1)
were generated at the Medical College of Wisconsin
using zinc finger nuclease genome editing techniques as
described by Geurts et al. (2009). Zinc finger nucleases
engineered to target the sequence CTTATTCCTT-
TGCAGCTGActttctAATGCAAGCGGATGGA were injec-
ted into SS/JrHsdMcwi rat embryos, which resulted in
a deletion of a 16 bp region of DNA that contains the
splice acceptor of exon 2 of myostatin (Fig. 1A). As the
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propeptide of myostatin is required for the proper folding
and assembly of the active myostatin peptide (Lee, 2004)
and both exons encode regions of the propeptide that
directly bind and stabilizemyostatin (Jiang et al. 2004), the
frameshift mutation caused by deleting the splice acceptor
of exon 2 was predicted to disrupt the production of
functional myostatin protein. Rats were backcrossed for
several generations to ensure stable germline transmission
of the mutant allele. Age-matched, wild-type rats from
the SS/JrHsdMcwi strain (MSTN+/+) were used as control
animals.
The animals were housed in ventilated micro-isolator
cages in specific pathogen-free conditions and provided
with water and a standard Lab Diet 5001 chow
(Purina Lab Diet, St Louis, MO, USA) ad libidum.
Pups were weaned 3 weeks after birth, genomic DNA
was obtained from tail biopsies, and MSTN genotype
was determined using end-point PCR with primers
(forward 5′-GGTGATTTTCTTCGTGTTTC-3′ and
reverse 5′-AACATTTGGGCTTTCCAT-3′) that flank the
targeted region of exon 2, resulting in a 102 bp amplicon
for the MSTN+ allele and 86 bp for the MSTN allele.
Male homozygous wild-type (MSTN+/+; n = 6) and
homozygous myostatin-deficient (MSTN/; n = 7) rats
were used in this study (Fig. 1B).
Rats were shipped to the University of Michigan at
6 weeks of age, and their growth was monitored until
use in experiments. At 24 weeks of age, rats were
placed into deep anaesthesia using sodium pentobarbital
(Vortex Pharmaceuticals, Dearborn, MI, USA) at a dose
of 40 mg/kg via intraperitoneal injection, and tissues
were removed for analysis. Left extensor digitorum longus
(EDL) and soleusmuscles were finelyminced and used for
biochemicalmeasurements. Right EDLand soleusmuscles
Figure 1. Genetic targeting approach and gross appearance of wild-type control (WT; MSTN+/+) and
myostatin knock-out (KO;MSTN/) rats
A, diagram demonstrating the strategy used to target and inactivate myostatin by deleting a portion of exon 2 of
myostatin that included the splice acceptor region. B, end-point PCR analysis using primers that flank the splice
acceptor of exon 2, demonstrating effective deletion of a 16 bp region of this gene. C, concentration of myostatin
(MSTN) in serum. D–F, gross appearance of 24-week-old MSTN+/+ and MSTN/ rats (scale bars represent 2 cm).
G, gross appearance of tibialis anterior muscles (scale bar represents 0.5 cm). Growth curves (H), heart mass (I) and
tibialis anterior (TA) muscle mass (J). In this and all subsequent figures, values are means ± SD; n = 6 forMSTN+/+
rats and n = 7 forMSTN/ rats. In this and all subsequent figures, differences were tested with Student’s unpaired
t tests; ∗P < 0.05 different from MSTN+/+ rats.
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were used for whole-muscle contractility measurements
and subsequent histology, and right tibialis anterior (TA)
muscles were used formeasurements of the contractility of
single muscle fibres. The left plantaris tendons were used
for mechanical properties measurements, while the right
side was used for histology. After muscles were removed,
1–2 ml of blood was obtained from the left ventricle, and
animals were killed by overdose of sodium pentobarbital
(100 mg/kg, intraperitoneal) followed by removal of the
heart.
Measurement of serum myostatin levels
Blood thatwas removed fromratswas allowed to coagulate
for 30 min, spun down at 1000g for 10 min, and serum
was removed and stored at −80°C until use. Myostatin
levels were measured in duplicate using an enzyme-linked
immunosorbent assay kit (R&D Systems, Minneapolis,
MN, USA), following the manufacturer’s instructions.
Before conducting the assay, serum samples were treated
with 1MHCl to releasemyostatin bound to the propeptide
or other carrier proteins, followed by neutralization in
1.2 M NaOH–0.5 M Hepes. Absorbance values were read
in a SpectraMax microplate reader (Molecular Devices,
Sunnyvale, CA, USA).
Gene expression
Gene expression was performed as previously described
(Gumucio et al. 2014;Mendias et al. 2012). Total RNAwas
isolated from EDL muscles, soleus muscles and plantaris
tendons using an miRNeasy kit (Qiagen, Valencia, CA,
USA) and treated with DNase I (Qiagen). The RNA
integrity was confirmed using a Bioanalyzer RNA system
(Agilent, SantaClara, CA,USA).Using anRT2 First Strand
mRNA or microRNA (miRNA) kit (Qiagen), RNA was
reverse transcribed and subsequently amplified in aCFX96
real-time thermal cycler (BioRad, Hercules, CA, USA)
using RT2 SYBR green-based qPCR reagents (Qiagen)
and primers for specific mRNA or miRNA species.
Most primers were purchased from Qiagen, with the
exception of IGF1Ea and IGF1Eb (Heinemeier et al. 2007).
Expression of target muscle mRNAs, tendon mRNAs and
muscle miRNAs were normalized to the expression of the
housekeeping transcripts β-actin, β2-microglobulin and
Rnu6, respectively, and then further normalized to the
expression of the MSTN+/+ group (Schmittgen & Livak,
2008).
Akt/mTOR multiplex analysis
A Luminex-based system was used to measure total
and phosphorylated proteins as previously described
(Sharma et al. 2012; Castorena et al. 2014). Briefly,
muscles were finely minced and placed in ice-cold
Tissue Protein Extraction Reagent (Thermo Scientific,
Rockford, IL, USA) supplemented with a protease
and phosphatase inhibitor cocktail (Thermo Scientific),
homogenized with a TissueRuptor (Qiagen) and vortexed
for 10 min at 4°C. Samples were then spun at
12,000g for 10 min, and the supernatant was collected
and stored at −80°C until use. Total protein content
was determined using a BCA protein assay (Thermo
Scientific), and 50 μg of total protein was analysed
usingMilliplex-MAP11-plexAkt/mTOR total protein and
phosphoprotein magnetic bead assays (EMD Millipore
Corporation, Billerica, MA, USA). These assays measure
the abundance of 11 total and phosphorylatedmembers of
the Akt/mTOR signalling pathway (AktSer473, GSK3αSer21,
GSK3βSer9, IGF1RTyr1135/1136, IRTyr1162/Tyr1163, IRS1Ser312,
mTORSer2448, p70S6KThr412, PTENSer380, RPS6Ser235/Ser236
and TSC2Ser939). Mean fluorescence intensity values of
analytes were measured in a MAGPIX system (Luminex
Corporation, Austin, TX, USA). The mean fluorescence
intensity of a particular phosphorylated protein was
normalized to the total protein, and this ratio was further
normalized to values from theMSTN+/+ group.
Hydroxyproline assay
The hydroxyproline content of muscles was measured
using a colorimetric assay as previously described
(Woessner, 1961; Mendias et al. 2006). Briefly, muscles
were dried for several hours at 110°C, weighed
immediately, and then hydrolysed in 500μl of 6 MHCl for
6h at 110°C.Thehydrolysatewas removed andneutralized
with an equal volume of 6 M NaOH. Known amounts of
L-hydroxyproline (Sigma, St Louis, MO, USA) were used
to construct a standard curve. Samples were assayed in
triplicate using a Spectramax M5 microplate reader at an
absorbance of 560 nm.
Measurement of whole-muscle contractile and
mechanical properties
Contractile properties of EDL and soleus muscles were
evaluated as previously described (Segal & Faulkner, 1985;
Mendias et al. 2006). Briefly a 4–0 silk suture was tied to
the proximal and distal tendons of intact EDL and soleus
muscles, immediately distal to the aponeuroses. Following
suture placement, muscles were then removed from the
animal and immediately placed in a bath that contained
Krebs mammalian Ringer solution supplemented with
0.3 mM tubocurarine chloride and 11 mM glucose.
The bath was maintained at 25°C and bubbled with a
mixture of 95% O2 and 5% CO2 to maintain a pH of 7.4.
The distal tendon of the muscle was tied to a dual-mode
servomotor/force transducer (Aurora Scientific, Aurora,
C© 2015 The Authors. The Journal of Physiology C© 2015 The Physiological Society
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ON, Canada) and the proximal tendon tied to a
fixed hook. Using square-wave pulses delivered from
platinum electrodes connected to a high-power current
stimulator (Aurora Scientific), muscles were stimulated to
contract. Custom-designed software (LabVIEW, National
Instruments,Austin, TX,USA) controlledpulse properties
and servomotor activity and recorded data from the
force transducer at 20 kHz. The voltage of pulses was
serially increased, and the muscle length was increased
or decreased to provide the length (Lo) that resulted in
maximal twitch force (Pt). Muscles were held at Lo and
stimulatedwithpulse trainsof 300ms forEDLmuscles and
900 ms for soleus muscles to generate isometric contra-
ctions. The stimulus frequency was increased until the
Po was achieved. To calculate sPo, Po was divided by
the physiological cross-sectional area (PCSA), which was
determined by dividing the muscle mass by the product
of fibre length (Lf) and 1.056 g cm−3, the density of
mammalian skeletal muscle.
After measurement of active force production, the
passive mechanical properties of muscles were measured.
Muscles were shortened to a value that was 0.3Lf shorter
than Lo, and subsequently stretched passively to a length
that was 0.3Lf greater than Lo at a velocity of 1Lf s−1.
After completion of passive stretch measurements, the
maximal isometric force was again measured to verify
that no mechanical stretch-induced injury had occurred.
Muscles were then removed from the bath, weighed and
immediately prepared for histology.
Permeabilized fibre contractility
The contractility of permeabilized muscle fibres from
the TA was measured as previously described (Mendias
et al. 2011; Gumucio et al. 2014). Briefly, fibre bundles
approximately 4–6 mm in length and 0.5–0.75 mm in
diameter were dissected from the deep aspect of the
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Figure 2. Messenger RNA expression from extensor digitorum longus (EDL; A) and soleus muscles (B)
Target genes are normalized to the stable housekeeping gene β-actin, and then further normalized to theMSTN+/+
group.
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muscle. Bundles were placed in skinning solution for
30 min and then in storage solution for 16 h at 4°C,
followed by storage at −80°C. On the day of single-fibre
testing, bundles were thawed slowly on ice, and individual
fibres were pulled frombundles using finemirror-finished
forceps. Fibres were then placed in a chamber containing
relaxing solution and secured at one end to a servomotor
(Aurora Scientific) and at the other end to a force trans-
ducer (Aurora Scientific) using two ties of 10–0 mono-
filament nylon suture at eachfibre end.TheLf was adjusted
to obtain a sarcomere length of 2.5 μm using a laser
diffraction measurement system. The average fibre CSA
was calculated assuming an elliptical cross-section, with
diameters obtained at five positions along the fibre from
high-magnification images at two different views (top and
side). The maximal fibre isometric force (Fo) was elicited
by immersing the fibre in a solution containing a supra-
physiological concentration of calcium. The specific force
of fibres (sFo) was calculated by dividing Fo by fibre CSA.
Fibres were categorized as fast or slow by examining their
force response to rapid, constant-velocity shortening, and
10 fast fibres were tested from each TA muscle from both
groups.
Figure 3. MicroRNA expression from EDL (A) and soleus
muscles (B)
Target genes are normalized to the stable housekeeping gene Rnu6,
and then further normalized to the MSTN+/+ group.
Histology
Muscles and tendons were rinsed and snap frozen in
Tissue-Tek (Sakura, Torrance, CA, USA) using isopentane
cooled in liquid nitrogen, and stored at −80°C until use.
Tissue was trimmed to obtain samples from themid-belly,
sectioned at a thickness of 10μm in a cryostat and stained
with Haematoxylin and Eosin or prepared for immuno-
histochemistry.Muscle fibre-type immunohistochemistry
was performed as described previously (Gumucio et al.
2014). Briefly, sections were permeabilized in 0.2%
TritonX-100 in PBS, blocked in 5%goat serum in PBS and
incubated with monoclonal antibodies (Developmental
Studies Hybridoma Bank, Iowa City, IA, USA) diluted
1:100 against type Imyosinheavy chain (BA-D5,mIgG2b),
type IIAmyosin heavy chain (SC-71, mIgG1) and type IIB
myosin heavy chain (BF-F3, mIgM). Primary antibodies
were detected with highly cross-adsorbed, goat secondary
antibodies that were conjugated to AlexaFluor probes
and diluted 1:300 (Life Technologies, Grand Island, NY,
USA). The absence of a fluorescence signal indicated
type IIX fibres. Wheat germ agglutin lectin conjugated
to AlexaFluor 488 (WGA-AF488; Life Technologies),
diluted 1:200, was used to identify extracellular matrix.
For plantaris tendons, sections were fixed with 4%
paraformaldehyde and incubated with WGA-AF488 and
with 4’,6-diamidino-2-phenylindole (Sigma) to identify
nuclei. Slides were imaged using a Zeiss Axiovert 200M
microscope outfitted with the ApoTome system (Carl
Zeiss, Thornwood, NY, USA). ImageJ software (NIH,
Bethesda, MD, USA) was used to perform quantitative
measurements.
Analysis of tendon mechanical properties
Plantaris muscle–tendon–bone units used for mechanical
properties analysis were wrapped in saline-soaked gauze
and stored at −20°C until use. Failure testing of plantaris
tendons was performed as previously described (Mendias
et al. 2008; Oak et al. 2014) using a modified ElectroForce
ELF3200 uniaxial testing system (Bose, Eden Prairie, MN,
USA) equipped with a 100 N load cell (Omega, Stamford,
CT, USA). Plantaris tendons were removed from rats
with their entheses and myotendinous junctions intact.
Bone and muscle were secured tightly to vice grips and
reinforced with ethyl cyanoacrylate. The tendon was pre-
loaded to 1.0 N, and two cameras (JAI, San Jose, CA, USA)
mounted 90 deg apart captured the front and side views of
the tendon, which was then used to calculate tendon CSA
by fitting width and length measurements to an ellipse,
as well as the starting tendon length (Lo). The specimen
was then stretched until failure at a rate of 10 mm s−1,
and the peak strain, peak stress, peak stiffness and energy
absorption were determined from testing.
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Statistical analysis
Data are presented as means ± SD. Differences between
MSTN+/+ and MSTN/ groups were tested using
Student’s unpaired t tests (α = 0.05). For growth
curve data, the Holm–Sidak method was used to
correct statistical significance to account for multiple
observations. Prism 6.0 software (GraphPad Software, San
Diego, CA, USA) was used for analysis.
Results
Deletion of the splice acceptor of exon 2 of myostatin
resulted in an 86% reduction in circulating myostatin
levels (Fig. 1C) and a grossly apparent increase in muscle
mass (Fig. 1D–G). The overall body mass of MSTN/
rats was 20% greater than that of MSTN+/+ rats at all
time pointsmeasured, and the general shape of the growth
curves was similar between the two genotypes (Fig. 1H).
No difference in heart mass was present (Fig. 1I), but
MSTN/ rats had a 42% increase in TA mass compared
with control rats (Fig. 1J).
For gene expression in EDL, MSTN/ rats had a 35%
reduction inATG5 expression, a 48% reduction in IGF1Eb
expression and a 62% decrease in IL-1β expression, but
no other differences were observed for genes related
to muscle hypertrophy and atrophy (Fig. 2A). Type I
collagen expression was increased by 125% and MMP-14
by 73% in MSTN/ rats, but otherwise the expression
of genes related to ECM synthesis or fibroblast makers
was similar between the two groups (Fig. 2A). In EDL,
expression of miR-31 was elevated in MSTN/ rats by
43%, miR-133a by 83%, miR-133b by 120%, miR-221
by 26%, miR-338 by 82% and miR-499 by 36%, while
miR-381 was downregulated by 83% (Fig. 3A). In soleus
muscles of MSTN/ rats, IL-10 expression elevated by
1046%overMSTN+/+ rats, but noother changes inmuscle
hypertrophy and atrophy genes were noted (Fig. 2B).With
Figure 4. Abundance of phosphoproteins from EDL (A) and soleus muscles (B)
The abundance of specific phosphoproteins was normalized to the total protein abundance, and then further
normalized to values from MSTN+/+ rats.
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ECM synthesis and fibroblast regulatory genes, expression
in soleus of MSTN/ rats was 47% greater for type I
collagen and MMP-2, 114% greater for MMP-3, 82%
greater for PDGFRα, 85% greater for TIMP1 and 55%
greater for TIMP2. For miRNAs in soleus, MSTN/ rats
had a 49% increase in miR-23a and miR-23b, a 39%
increase in miR-29b, a 31% increase in miR-126 and
miR-133a, a 43% increase inmiR-133b and a 23% increase
in miR-206 and miR-338 expression (Fig. 3B).
We then evaluated the relative content of various
phosphoproteins and collagen in muscles. For the EDL
(Fig. 4A), there were increases of 52% in p-AktSer473,
28% in p-IGF1RTyr1135/1136, 33% in p-mTORSer2448,
27% in p-PTENSer380 and 25% in RPS6Ser235/Ser236 for
MSTN/ rats vs. MSTN+/+ rats. No differences were
observed in p-GSK3αSer21, p-GSK3βSer9, p-IRTyr1162/Tyr1163,
p-IRS1Ser312, p-p70S6KThr412 or p-TSC2Ser939. In soleus
muscles (Fig. 4B), MSTN/ rats had a 25% increase in
p-IGF1RTyr1135/1136 and a 30% increase in p-mTORSer2448,
but no differences were observed in the levels of other
phosphoproteins. For collagen content, no differences in
hydroxyproline content were observed betweenMSTN+/+
andMSTN/ rats for EDL and soleus muscles (Fig. 5).
For muscle contractility measurements, at the level of
the single muscle fibre, no differences in CSA, Fo or sFo
were observed (Fig. 6). For the EDL muscle, there was a
33% increase in mass, a 31% increase in PCSA, a 57%
increase in Po and no difference in sPo production in
Figure 5. Hydroxyproline (hyp) content of EDL (A) and soleus
muscles (B)
Total hydroxyproline was normalized to the dry mass of muscles.
Figure 6. Contractility of permeabilized TA muscle fibres
A, muscle fibre cross-sectional area (CSA). B, maximal isometric force
(Fo). C, specific maximal isometric force (sFo).
MSTN/ rats (Fig. 7A–D). No differences in muscle
length or in passive mechanical properties were observed
(Table 1), and fibres in both genotypes appeared grossly
healthy (Fig. 8A). The MSTN/ rats had a 37% increase
in overall fibres per muscle, with an approximate 20%
increase in the size of type IIA, IIB, IIX, IIA/IIX and
IIB/IIX fibres (Fig. 8C and D). There was an overall 80%
reduction in the proportion of type I fibres and a 26%
reduction in type IIA/IIX fibres in MSTN/ rats, with a
25% increase in the number of type IIB fibres (Fig. 8E).
Soleus muscles of MSTN/ rats demonstrated a 20%
increase inmass, a 22%increase inPCSA, a 20%increase in
Po and no difference in sPo compared withMSTN+/+ rats
(Fig. 7E–H). Soleus muscle lengths were similar between
genotypes, but MSTN/ rats had a 12% reduction in
peak passive stress and a 14% reduction in passive energy
absorption, with no differences in peak passive load or
stiffness (Table 1). Overall fibre appearance was generally
healthy (Fig. 8A). The MSTN/ rats had a 45% increase
in overall fibres per muscle (Fig. 8F). No change in fibre
area was observed, butMSTN/ rats had a 6% reduction
in type I fibres (Fig. 8G and H).
After measuring muscle mechanics, morphology and
biochemistry, we next determined the structure and
function of tendons. No difference in absolute TA or
plantaris tendonmasses were observed, although the ratio
of TA tendon to muscle mass was reduced by 26% in
MSTN/ rats (Fig. 9A and B). The overall CSA and cell
density of plantaris tendons was similar between the two
groups (Fig. 9C and D). Regarding the measurement of
mechanical properties, the initial measurements of length
and CSA were made when tendons were held at a length
that produced 1 N of total load, which was just past the
toe region of the stress-strain graph. No difference in Lo
was observed, but the overall nominal CSA of tendons
was reduced by 23% in MSTN/ rats. Tendons were
then stretched to yield, and although a 20% reduction
in peak strain was observed, no differences in peak stress,
peak stiffness or energy absorption during the stretchwere
observed (Fig. 10).
Finally, we measured the expression of several
genes important in determining the composition and
mechanical properties of tendon ECM, as well as
genes involved in regulating tendon fibroblast activity.
Compared with MSTN+/+ rats, MSTN/ rats had
increases of 141% forMMP-9, 524% forMMP-14, 2112%
forEgr2 and84%formohawk, but otherwisenodifferences
in gene expression were observed (Fig. 11).
Discussion
Myostatin has one of the greatest effects on skeletal
musclemass of any single signallingmolecule, with genetic
deficiencies of myostatin in mice resulting in gains of
muscle mass of 50–100% or more (McPherron et al.
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2006; Mendias et al. 2006; Lee, 2007; Gentry et al. 2011).
In the present study, genetic inactivation of myostatin
through the induction of a zinc finger nuclease-mediated
frameshiftmutation resulted in rats withmarked increases
in muscle mass. Although the gains in muscle mass of
MSTN/ rats compared with MSTN+/+ rats was not
quite as great as the extent previously reported in EDL
and soleus muscles of mice (Mendias et al. 2006), the
MSTN/ rats had improvements in force production that
were generally greater than those observed in mice. The
dramatic stiffening of muscle and tendon ECMpreviously
observed inmyostatin-deficientmice (Mendias et al. 2006,
2008) did not occur in myostatin-deficient rats. The over-
all results from this study indicate that inactivation of
myostatin in rats resulted in marked increases in muscle
mass and improved force production without some of the
detrimental effects on muscle and tendon contractile and
mechanical properties observed in myostatin-deficient
mice.
Myostatin appears to regulate muscle fibre size by inter-
acting with both the protein synthesis and degradation
pathways in muscle fibres. Atrogin-1 and MuRF-1, which
are induced in response to myostatin, are among the
chief E3 ubiquitin ligases expressed in skeletal muscle that
direct the polyubiqutination of proteins to target them for
proteolysis by the 26S proteasome (Lokireddy et al. 2011;
Mendias et al. 2011; McFarlane et al. 2012). Autophagy is
another important cellular process responsible for protein
degradation in skeletal muscle, and myostatin signalling
can activate this pathway and trigger the formation
of autophagosomes (Lee et al. 2011). Myostatin also
inhibits protein synthesis by blocking the IGF-1/PI3K/Akt
pathway and subsequent activation of p70S6K (Yang
et al. 2007; Amirouche et al. 2009; Trendelenburg et al.
2009). In the present study, no differences in atrogin-1 or
MuRF-1 were observed betweenMSTN+/+ andMSTN/
rats in both EDL and soleus muscles. ATG5, which is
important for phagophore elongation and maturation
(Sandri, 2011), was downregulated in EDL muscles of
MSTN/ rats, but no differences in expression were pre-
sent for other key regulators of autophagy, ATG16L1,
beclin-1 or Vps34. Interleukin-1β and interleukin-6
are atrophy-inducing cytokines, whose activity can be
countered by interleukin-10 (Mun˜oz-Ca´noves et al. 2013;
Thompson et al. 2013). Interleukin-1βwas downregulated
in EDL muscles of MSTN/ rats, while IL-10 was
markedly induced in soleus muscles of MSTN/ rats.
Several of the miRNAs involved in the adaptation of
muscle to mechanical loading, termed myomiRs (Kirby
& McCarthy, 2013), were differentially regulated by
inactivation of myostatin. Reductions in miR-1 and
miR-133a, which target IGF-1Ea and its receptor, are
downregulated during hypertrophy in mice (McCarthy
& Esser, 2006), but in the present study no differences
in miR-1 were observed and miR-133a was elevated in
bothmuscles fromMSTN/ rats. Although no difference
in IGF-1Ea expression was observed, EDL and soleus
muscles ofMSTN/ rats had increased levels of p-IGF-1
receptor and p-mTOR. Further activation of downstream
components of the IGF-1 pathway in EDL muscles is
supported by increased levels of p-PTEN, and although
p-p70S6K levels were not different, the levels of the
translation–regulation protein p-RPS6 were elevated in
MSTN/ rats.
While the results regarding components of the muscle
hypertrophy pathway were anticipated, the minimal
Figure 7. Mass and contractility of EDL (A–D) and soleus muscles (E–H)
A and E, whole muscle mass. B and F, physiological cross-sectional area (PCSA). C and G, maximal isometric force
(Po). D and H, specific maximal isometric force (sPo).
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Table 1. Twitch and passive mechanics measurements from extensor digitorum longus and soleus muscles ofMSTN+/+ andMSTN/
rats
Parameter MSTN+/+ MSTN/
Extensor digitorum longus
Muscle mass (mg) 170.7 ± 7.6 224.6 ± 4.4∗
Lo (mm) 33.8 ± 0.8 33.9 ± 1.3
Lf (mm) 13.5 ± 0.3 13.6 ± 0.5
Peak twitch force (mN) 928.1 ± 70.6 1235 ± 179∗
Specific peak twitch force (mN mm−2) 78.0 ± 5.3 78.8 ± 9.5
Time-to-peak twitch tension (ms) 27.0 ± 0.7 27.5 ± 1.2
Half-relaxation time (ms) 21.2 ± 2.1 17.8 ± 1.2∗
Maximal twitch dP/dt (mN ms−1) 62.5 ± 6.5 79.7 ± 20.1∗
Peak passive load (mN) 588.7 ± 289.0 568.5 ± 341.0
Peak passive stress (mN mm−2) 49.9 ± 25.6 36.9 ± 23.4
Peak passive stiffness (mN mm−2) 499.6 ± 159.7 465.5 ± 200.9
Passive stretch energy absorption (mJ g−1) 4.2 ± 2.2 3.3 ± 2.0
Soleus
Muscle mass (mg) 154.8 ± 8.0 185.5 ± 10.6∗
Lo (mm) 31.4 ± 0.8 31.4 ± 1.4
Lf (mm) 18.8 ± 0.5 18.8 ± 0.8
Peak twitch force (mN) 377.2 ± 68.2 452.8 ± 65.4∗
Specific peak twitch force (mN mm−2) 47.5 ± 7.5 47.0 ± 6.4
Time-to-peak twitch tension (ms) 89.3 ± 10.1 77.1 ± 5.0∗
Half-relaxation time (ms) 164.5 ± 19.3 124.5 ± 14.7∗
Maximal twitch dP/dt (mN ms−1) 11.1 ± 1.8 15.2 ± 2.6∗
Peak passive load (mN) 2392.0 ± 248.9 2596 ± 448.2
Peak passive stress (mN mm−2) 301.7 ± 22.1 265.8 ± 35.0∗
Peak passive stiffness (mN mm−2) 676.0 ± 175.2 789.6 ± 82.4
Passive stretch energy absorption (J kg−1) 32.5 ± 0.7 27.8 ± 5.6∗
Abbreviations: dP/dt, rate of force development; Lf, fibre length; Lo, length that results in maximal twitch force; MSTN+/+, wild-type
control; and MSTN/, myostatin knock-out. Values are means ± SD; n = 6 for MSTN+/+ rats and n = 7 for MSTN/ rats. Differences
were tested with Student’s unpaired t tests
∗significantly different from MSTN+/+ rats (P < 0.05).
involvement of atrophy genes was surprising. The
discrepancies between the present findings and previously
reported studies of myostatin are likely to be due to two
factors. First, most of the studies on myostatin signalling
have been conducted in cultured murine myotubes using
high doses of myostatin, and it is possible that findings
from this system are unique to the in vitro environment,
where it is possible to control levels of growth factors and
othermedia components tightly. Second, a species-specific
difference in response to myostatin may be present.
Even within the in vitro environment, murine myo-
tubes robustly activate canonical atrophy pathways in
response to myostatin, while human myotubes are far less
responsive (Trendelenburg et al. 2009; Lokireddy et al.
2011; McFarlane et al. 2012). The results from the pre-
sent study suggest that in rats, myostatin deficiency has
little impact on atrophy-related genes in vivo, and this is
in agreement with recent work that posited the role of
myostatin signalling in muscle is to prevent activation of
hypertrophy signalling pathways, not to induce muscle
atrophy pathways directly (Sartori et al. 2013).
Most studies have indicated that blocking myostatin
leads to an increase in Po at the whole-muscle level, but
sPo has been reported either to decrease (Mendias et al.
2006; Matsakas et al. 2007; Schirwis et al. 2013) or not to
change (Gentry et al. 2011; Murphy et al. 2011). Using in
vitro measurements from 10- to 12-month-old mice, we
found that compared with wild-type control animals the
myostatin-deficient mice demonstrated a 63% increase in
PCSA, a 34% increase in Po and an 18% decrease in sPo
for the EDL, and a 30% increase in PCSA and Po, with
no change in sPo for the soleus (Mendias et al. 2006).
The reduction in sPo for EDL muscles led us to study
changes in contractility at the single-fibre level, which
demonstrated that compared with wild-type mice, fibres
frommyostatin-deficient mice had an increase in CSA, no
change in Fo and a subsequent reduction in sFo (Mendias
et al. 2011). These findings were supported by Qaisar et al.
(2012), who also observed a decrease in sFo in single fibres
from myostatin-deficient mice.
We postulated that the reason EDL muscles from
myostatin-deficient mice had greater mass and Po at the
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whole-muscle level was due to the dramatic 66% increase
in the number of fibres present in their muscles (Mendias
et al. 2006, 2011). Furthermore, the decrease in protein
degradation in myostatin-deficient mice was likely to
lead to a reduction in the ability to target proteins to
the ubiquitin–proteasome system efficiently in normal
homeostatic conditions, resulting in an accumulation
of proteins that physically took up space but did not
contribute to force production and a subsequent decrease
in sPo. This is supported by other studies, which have
reported the presence of swollen fibres and inclusion body
protein aggregates in the muscles of myostatin-deficient
mice (Amthor et al. 2007; Gentry et al. 2011).
In the present study, at the whole-muscle level the
MSTN/ rats had an increase in PCSA and fibre
abundance and, much to our surprise, had an increase in
Figure 8. Fibre-type distribution and size of EDL (B–E) and soleus muscles (F–H)
A, representative images of Haematoxylin- and Eosin-stained sections from EDL and soleus muscles demonstrating
the grossly healthy appearance of fibres. B, representative image from an EDL muscle demonstrating the different
fibre types measured. C and F, fibres per muscle. D and G, size of fibres. E and H, distribution of fibres.
Figure 9. Tendon mass, size and cell density
A, mass of tibialis anterior (TA) and plantaris (Pln) tendons. B, TA tendon mass normalized to the mass of its
muscle. Cross-sectional area (CSA; C) and cell density measurements (D) from full-thickness histological sections
taken from the mid-belly of the tendon.
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Po without a reduction in sPo and no differences in CSA,
Fo or sFo at the single-fibre level. No grossly apparent
inclusion bodies, centrally located nuclei, swollen or
ragged fibres or other pathological features were noted
in muscle sections. The EDL muscles of MSTN/ rats
had modest increases in the CSA of many muscle fibre
types, as well as a reduction in the percentage of type I
fibres and an increase in type IIB fibres, which is consistent
with observations in myostatin-deficient mice and cattle
(Deveaux et al. 2001; Girgenrath et al. 2005; Gentry
et al. 2011). No differences were present for soleus
muscles, though. When combined, these results indicate
that the genetic deficiency of myostatin in rats causes
increased force production at the whole-muscle level
chiefly through hyperplasia, with modest contributions
from hypertrophy. Furthermore, the muscle appeared
grossly healthy, without a decrease in sPo and sFo that was
previously observed in some reports in mice, suggesting
that the negative effects of myostatin inhibition onmuscle
contractility are not present in rats.
In addition to muscle fibres, myostatin appears to
regulate the composition andmechanical properties of the
muscle ECM, including tendons. Treatment of cultured
mousemuscle cells,muscle fibroblasts or tendonfibroblast
cells with myostatin induces the expression of type I
collagen (Mendias et al. 2006, 2008; Li et al. 2008), and
inhibition of myostatin in injured mice and in mdx mice
reduced fibrosis (McCroskery et al. 1997; Wagner et al.
2002). The collagen content of myostatin-deficient mice
is reduced by 73% in EDL muscles, with no differences
observed for soleus muscles (Mendias et al. 2006). The
collagen content of cattle with deficiencies in myostatin
Figure 10. Mechanical properties of
tendons tested until yield
A, starting tendon length (Lo). B, nominal
CSA. C, peak strain to yield. D, peak stress
to yield. E, peak stiffness to yield. F, energy
absorption during the test. G, stress–strain
graphs of samples.
Figure 11. Messenger RNA expression from tendons
Target genes are normalized to the stable housekeeping gene β2-microglobulin, and then further normalized to
the MSTN+/+ group.
C© 2015 The Authors. The Journal of Physiology C© 2015 The Physiological Society
J Physiol 593.8 Muscle and tendon mechanics of myostatin knock-out rats 2049
is either not different or modestly reduced depending on
the muscle and the analysis technique (Ngapo et al. 2002;
Raes et al. 2003).
In the present study, surprisingly we observed a mild
increase in collagen expression in both EDL and soleus
muscles of MSTN/ rats, as well as an increase in
MMP-14 in EDL, and an increase inMMP-2 andMMP-9
in soleusmuscles. Inhibitors ofmatrixmetalloproteinases,
TIMP-1 and TIMP-2, as well as the fibroblast progenitor
cell marker PDGFRα (Joe et al. 2010), were moderately
upregulated inMSTN/ soleus muscles. Several miRNAs
associated with increased collagen expression, miR-31,
miR-221 and miR-338 (Gumucio et al. 2013), were
also upregulated in MSTN/ muscles. However, despite
modest increases in type I collagen expression, no
differences in relative hydroxyproline content of muscles
were observed. While we were surprised to see a mild
induction in type I collagen expressionwith no differences
in hydroxyproline content, the corresponding increase in
MMP expressioncould indicate that theECMofMSTN/
rats is undergoing greater turnover and remodelling to
accommodate the increased relative size and hyperplasia
ofMSTN/ muscles.
Compared with wild-type control animals, the tendons
of myostatin-deficient mice are 40% smaller, have a
45% reduction in fibroblast density and have marked
reductions in the expression of type I collagen and the
tendon cell proliferation and ECM production genes
scleraxis and tenomodulin (Mendias et al. 2008). The
tendons of these mice are also 14-fold stiffer and have
a peak strain less than half that of wild-type mice
(Mendias et al. 2008). Myostatin expression in tendons
is downregulated in rats after unloading, and treatment
of injured tendons with myostatin increased CSA but
decreased peak stress of the tissue (Eliasson et al. 2009).
Based on these findings, we anticipated that we would
see dramatic stiffening and hypocellularity of tendons
in MSTN/ rats, but this was not observed. Although
relative tendon mass was reduced, the absolute mass
of tendons was not different between MSTN+/+ and
MSTN/ rats. While no differences in tendon CSA were
observed in histological measurements, nominal tendon
CSA was reduced slightly when tendons were loaded to
1 N of force. No differences in peak stress were present,
and although peak strain was reduced by about a fifth,
a failure this high is far outside of the normal physio-
logical ranges of strain in which tendons operate. For gene
expression, no difference in type I collagen expression was
observed, and modest elevations inMMP-9 andMMP-14
were present in MSTN/ tendons. There were also no
differences between MSTN+/+ and MSTN/ rats for the
expression of genes related to fibroblast proliferation and
remodelling, such as scleraxis or tenomodulin. This is in
contrast to tendons frommyostatin-deficient mice, which
have marked reductions in type I collagen, scleraxis and
tenomodulin (Mendias et al. 2008). Curiously, though, a
robust 20-fold increase in the expressionofEgr2wasnoted.
Early growth response protein 2 (Egr2) is a member of
the early growth response transcription factor family that
is important in the differentiation and ECM production
of tendon fibroblasts (Le´jard et al. 2011). Expression of
Egr2 is robustly induced in response to transforming
growth factor-β signalling, but not activin signalling
(Mazhawidza et al. 2005; Fang et al. 2011). It is possible
that anothermember of the transforming growth factor-β
superfamilywhich induces fibroblast cell proliferation and
collagen synthesis, but does not signal through the activin
receptors, is upregulated to compensate for the absence
of signals from myostatin, resulting in the observed
induction in Egr2 and overall similar ECM composition
and fibroblast gene expression patterns.
There are several limitations to this study. While the
currently available genetic techniques are able to remove
large regions of the genome in mice, the ability to
manipulate the rat genome is more limited. As such,
the mutation was targeted to the myostatin propeptide
region to disrupt the proper folding and processing of
myostatin. Although there is a small amount of myo-
statin remaining in circulation, because the propeptide
is required for proper folding of myostatin, it is not
clear whether the myostatin found in MSTN/ rats has
any biological activity. We evaluated only male rats at 6
months of age, and further studies looking at both sexes
and different time points will no doubt be informative.
Rats in this study lacked myostatin throughout their life-
span, and the observed hyperplasia in MSTN/ muscles
is likely to have occurred as a result of developmental
mechanisms, with hyperplasia unlikely to occur if myo-
statin is inhibited postnatally.We did not evaluate changes
in mechanical properties of the toe region of tendons and
did not evaluate changes in hysteresis. Finally, while we
measured the expression of several mRNAs, we did not
quantify protein levels, and it is possible that changes
in mRNA do not reflect changes in protein abundance.
Despite these limitations, this work provided novel insight
into changes in the structure and function of skeletal
muscles and tendons in a large rodent model of myostatin
deficiency.
As the inhibition of myostatin can result in substantial
increases in total muscle mass and reductions in fibrosis,
there has been much interest in the development of
therapeutic inhibitors of myostatin for the treatment
of a wide variety of muscle-wasting diseases (Gumucio
& Mendias, 2012). Although there have been several
encouraging preclinical studies in mouse models of
diseases and injuries, the impaired contractile function
and pathological changes to muscle fibres and their
ECM in otherwise healthy mice has provided some
pause with regard to the ability to implement therapies
that target myostatin safely in patients. The nature of
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myostatin inhibition in the present study is different
from the pharmacological approaches that would occur
therapeutically, but the pathological changes reported
in some mouse models of myostatin deficiency did not
occur in this rat model. Additionally, there has been
concern about the potential abuse of myostatin inhibitors
for doping purposes. However, no differences in force
production were observed at the level of single fibres,
and the overall increase in whole-muscle force production
occurred mostly due to hyperplasia. While further studies
are necessary, as hyperplasia does not occur in adult
humans (Lexell, 1995), it is unlikely that blocking myo-
statin in otherwise healthy muscle fibres would result
in noticeable improvements in muscle force production.
For injuries or diseases that involve an upregulation in
myostatin, therapeutic inhibition may still help to reduce
muscle atrophy and lessen strength loss. Overall, the rat
model of genetic deficiency of myostatin has provided
important insight into species-specific changes in muscle
and tendonmorphologyandmechanics andwill behelpful
in further basic and translational physiological studies.
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